3002: Human blood/ animal blood/ antisera, etc/ vaccines, toxins, etc
COMESA
300210
Antisera & other blood fractions & modified immunological products, whether/not obt. by means of biotechnological processes
300220
Vaccines for human medicine
300230
Vaccines for veterinary medicine
300290
Human blood; animal blood prepared for therapeutic/prophylactic/diagnostic uses; toxins, cultures of micro-organisms (excl. yeasts) & similar products
Goods are considered originating if they have been produced in the member States wholly or partially from materials imported from outside the member States or of undetermined origin provided that:
- The c.i.f. value of those materials does not exceed 60% of the total cost of the materials used in the production of the goods;
- The value added resulting from the process of production accounts for at least 35% of the ex-factory cost of the goods;
- Manufacture from materials classified in a heading other than that of the product
SADC
300210
Antisera & other blood fractions & modified immunological products, whether/not obt. by means of biotechnological processes
300220
Vaccines for human medicine
300230
Vaccines for veterinary medicine
300290
Human blood; animal blood prepared for therapeutic/prophylactic/diagnostic uses; toxins, cultures of micro-organisms (excl. yeasts) & similar products
- Manufacture in which all the materials used are classified within a heading other than that of the product
EAC
300210
Antisera & other blood fractions & modified immunological products, whether/not obt. by means of biotechnological processes
300220
Vaccines for human medicine
300230
Vaccines for veterinary medicine
300290
Human blood; animal blood prepared for therapeutic/prophylactic/diagnostic uses; toxins, cultures of micro-organisms (excl. yeasts) & similar products
Goods are considered originating if they have been produced in the member States wholly or partially from materials imported from outside the member States or of undetermined origin provided that:
- The c.i.f. value of those materials does not exceed 60% of the total cost of the materials used in the production of the goods;
- The value added resulting from the process of production accounts for at least 35% of the ex-factory cost of the goods;
- Manufacture from materials classified within a heading other than that of the product - Manufacture from any other heading is recognized as a substantial process.
EU GSP
Applicable HS codes (includes 6 exceptions)
300210
Antisera & other blood fractions & modified immunological products, whether/not obt. by means of biotechnological processes
300220
Vaccines for human medicine
300230
Vaccines for veterinary medicine
300290
Human blood; animal blood prepared for therapeutic/prophylactic/diagnostic uses; toxins, cultures of micro-organisms (excl. yeasts) & similar products